Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study

Oscar Arrieta, Rosa M Michel Ortega, Geraldine Villanueva-Rodríguez, Maria G Serna-Thomé, Diana Flores-Estrada, Consuelo Diaz-Romero, Cindy M Rodríguez, Luis Martínez, Karla Sánchez-Lara, Oscar Arrieta, Rosa M Michel Ortega, Geraldine Villanueva-Rodríguez, Maria G Serna-Thomé, Diana Flores-Estrada, Consuelo Diaz-Romero, Cindy M Rodríguez, Luis Martínez, Karla Sánchez-Lara

Abstract

Background: A frequent manifestation of advanced NSCLC is malnutrition, even though there are many studies which relate it with a poor survival, its relation with toxicity has not yet been consistently reported. The aim of this study was to associate malnutrition and albumin serum levels with the occurrence of chemotherapy-induced toxicity in cisplatin plus paclitaxel chemotherapy-treated NSCLC.

Methods: We prospectively evaluated 100 stage IV NSCLC patients treated with paclitaxel (175 mg/m2) and cisplatin (80 mg/m2). Malnutrition was assessed using SGA prior treatment. Neutrophil Lymphocyte Ratio (NLR) and the Platelet Lymphocyte Ratio (PLR) were used to determine the presence of systemic inflammatory response (SIR) and were related to the development of toxicity. Toxicity was graded according to NCI CTCAE version 3.0 after two chemotherapy cycles.

Results: Median age was 58 +/- 10 years, 51% of patients were malnourished, 50% had albumin < or =3.0 mg/mL. NLR > or = 5 was associated with basal hypoalbuminemia (mean ranks, 55.7 vs. 39 p = 0.006), ECOG = 2 (47.2 vs. 55.4 p = 0.026) and PLR > or = 150 were significantly related with a basal body mass index < or =20 (56.6 vs. 43.5; p = 0.02) and hypoalbuminemia (58.9 vs. 41.3; p = 0.02). Main toxicities observed after 2 cycles of chemotherapy were alopecia (84%), nausea (49%), neuropathy (46%), anemia (33%), lymphopenia (31%), and leukopenia (30%). Patients malnourished and with hypoalbuminemia developed more chemotherapy-induced toxicity overall when compared with those without malnutrition (31 vs 22; p = 0.02) and normal albumin (mean ranks, 62 vs 43; p = 0.002), respectively. Hypoalbuminemia was associated with anemia (56 vs 47; p = 0.05), fatigue (58 vs 46; p = 0.01), and appetite loss (57.1 vs 46.7; p = 0.004) compared with normal albumin. PLR > or = 150 was related with the development of toxicity grade III/IV (59.27 vs. 47.03 p = 0.008) and anemia (37.9 vs 53.8 p = 0.004).

Conclusion: SIR parameters were associated with malnutrition, weight loss and hypoalbuminemia. Chemotherapy-induced toxicity in NSCLC patients treated with paclitaxel and cisplatin was associated with malnutrition and hypoalbuminemia. Early nutritional assessment and support might confer beneficial effects.

References

    1. Danaei G, Hoorn S Vander, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366(9499):1784–93. doi: 10.1016/S0140-6736(05)67725-2.
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008;58(2):71–96. doi: 10.3322/CA.2007.0010.
    1. Lazcano Ponce EC, Tovar Guzman V, Meneses Gonzalez F, Rascon Pacheco RA, Hernandez Avila M. Trends of lung cancer mortality in Mexico. Archives of medical research. 1997;28(4):565–70.
    1. Ginsberg RJ, Vokes EE, Raben A. In: Cancer: Principles & Practice. 8. De Vita VT, Hellman S, Rosenberg SA, editor. Lippincott Williams & Wilkins; 1997. Cancer of the lung, section 2: non-small cell lung cancer; p. 858.
    1. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17(10):3188–94.
    1. Harper P. Current clinical practices for ovarian cancers. Seminars in oncology. 2002;29(3 Suppl 8):3–6. doi: 10.1053/sonc.2002.33525.
    1. Seidman AD. Monotherapy options in the management of metastatic breast cancer. Seminars in oncology. 2003;30(2 Suppl 3):6–10.
    1. Rinaldi M, Cauchi C, Gridelli C. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol. 2006;17(Suppl 5):v64–7. doi: 10.1093/annonc/mdj953.
    1. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20(20):4191–8. doi: 10.1200/JCO.2002.03.054.
    1. Rowinsky EK, Donehower RC. Paclitaxel (taxol) The New England journal of medicine. 1995;332(15):1004–14. doi: 10.1056/NEJM199504133321507.
    1. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55(1):5–30. doi: 10.2165/00003495-199855010-00002.
    1. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998;16(5):1811–9.
    1. Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. Japanese journal of clinical oncology. 2003;33(12):626–30. doi: 10.1093/jjco/hyg116.
    1. Timmer-Bonte JN, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, Huitema AD, Tjan-Heijnen VC. Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2008;60(2):222–30.
    1. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Annals of neurology. 1994;35(3):304–11. doi: 10.1002/ana.410350310.
    1. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993;11(10):2010–20.
    1. Gordon JN, Green SR, Goggin PM. Cancer cachexia. Qjm. 2005;98(11):779–88. doi: 10.1093/qjmed/hci127.
    1. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–6. doi: 10.1097/MCO.0b013e32832a7902.
    1. Vassallo JABE. Actualización Ponderada de los Factores de Riesgo del Cáncer. Montevideo: Comisión Honoraria de Lucha contra el Cáncer; 2003.
    1. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42(1):31–41. doi: 10.1016/j.ejca.2005.07.026.
    1. Ottery FD. Cancer cachexia: prevention, early diagnosis, and management. Cancer practice. 1994;2(2):123–31.
    1. Lochs H, Dervenis C. Malnutrition--the ignored risk factor. Digestive diseases (Basel, Switzerland) 2003;21(3):196–7.
    1. Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. European journal of clinical nutrition. 2002;56(8):779–85. doi: 10.1038/sj.ejcn.1601412.
    1. Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN. Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. Jpen. 1984;8(2):153–9.
    1. Kuzuya M, Kanda S, Koike T, Suzuki Y, Satake S, Iguchi A. Evaluation of Mini-Nutritional Assessment for Japanese frail elderly. Nutrition (Burbank, Los Angeles County, Calif) 2005;21(4):498–503.
    1. Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A. Malnutrition among gynaecological cancer patients. European journal of clinical nutrition. 2007;61(5):642–6.
    1. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73(3-4):215–20. doi: 10.1159/000127412. Epub 2008 Apr 17.
    1. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425–8. doi: 10.1016/j.jtcvs.2008.05.046. Epub 2008 Aug 29.
    1. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4. doi: 10.1002/jso.20329.
    1. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197(4):466–72. doi: 10.1016/j.amjsurg.2007.12.057. Epub 2008 Jul 17.
    1. Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003;11(10):652–9. doi: 10.1007/s00520-003-0486-0.
    1. Busch E, Verazin G, Antkowiak JG, Driscoll D, Takita H. Pulmonary complications in patients undergoing thoracotomy for lung carcinoma. Chest. 1994;105(3):760–6. doi: 10.1378/chest.105.3.760.
    1. Bashir Y, Graham TR, Torrance A, Gibson GJ, Corris PA. Nutritional state of patients with lung cancer undergoing thoracotomy. Thorax. 1990;45(3):183–6. doi: 10.1136/thx.45.3.183.
    1. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–62. doi: 10.1017/S0029665108007131. Epub 2008 May 1.
    1. Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pellicciotta M, Ceribelli A, De Marco S, Facciolo F, Cognetti F. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res. 2004;23(1):25–32.
    1. Paal K, Shkarupin A. Paclitaxel binding to the fatty acid-induced conformation of human serum albumin--automated docking studies. Bioorganic & medicinal chemistry. 2007;15(24):7568–75. doi: 10.1016/j.bmc.2007.09.006.
    1. Kratz F, Ehling G, Kauffmann HM, Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Human & experimental toxicology. 2007;26(1):19–35. doi: 10.1177/0960327107073825.
    1. D'Angio RG. Is there a role for albumin administration in nutrition support? The Annals of pharmacotherapy. 1994;28(4):478–82.
    1. Guthrie RD Jr, Hines C Jr. Use of intravenous albumin in the critically ill patient. The American journal of gastroenterology. 1991;86(3):255–63.
    1. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–30. doi: 10.1038/sj.bjc.6601242.
    1. Holroyde CP, Reichard GA Jr. General metabolic abnormalities in cancer patients: anorexia and cachexia. The Surgical clinics of North America. 1986;66(5):947–56.
    1. Wilson DO, Rogers RM, Hoffman RM. Nutrition and chronic lung disease. The American review of respiratory disease. 1985;132(6):1347–65.
    1. Morss Dy S. Enteral and Parenteral Nutrition in Terminally Ill Cancer Patients: A Review of the Literature. Am J Hosp Palliat Care. 2006;23:369–77. doi: 10.1177/1049909106292167.
    1. Casado-Cobo SCR. Dietary interventions in Cancer. Rev Oncol. 2004;6:496–500.
    1. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of aninflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90(9):1704–6.
    1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to in6lammation. N Engl J Med. 1999;340:448–454. doi: 10.1056/NEJM199902113400607.
    1. Nakahara Y, Mochiduki Y, Miyamoto Y, Nakahara Y, Katsura Y. Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer. 2005;104(6):1271–80. doi: 10.1002/cncr.21290.
    1. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Adizzoia A, Gardani GS. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers. 2004;19(2):135–40.
    1. Sung JBG, Joshi M, Bochicchio K, Costas A, Tracy K, Scalea TM. Admission serum albumin is predicitve of outcome in critically ill trauma patients. Am Surg. 2004;70:1099–102.
    1. Kuzuya MIS, Enoki H, Okada K, Iguchi A. Is serum albumin a good marker for malnutrition in the physically impaired elderly? Clin Nutr. 2007;26:84–90. doi: 10.1016/j.clnu.2006.07.009.
    1. Win TRA, Wells F, Laroche C. The incidence and impact of low body mass index on patients with operable lung cancer. Clin Nutr. 2007;26:440–43. doi: 10.1016/j.clnu.2007.01.009.
    1. Numeroso F, Barilli AL, Delsignore R. Prevalence and significance of hypoalbuminemia in an internal medicine department. European journal of internal medicine. 2008;19(8):587–91. doi: 10.1016/j.ejim.2007.04.029.
    1. Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987;5(1):113–24.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться